Nanterre, 19 May 2025
Publication of the Pitch Book “Why invest in VINCI, a global leader in infrastructure”
VINCI announces the publication of its Pitch Book “Why invest in VINCI, a global leader in infrastructure” on its website: Annual reports and presentations | VINCI
The main objective of this summary presentation, which is primarily intended for investors, is to highlight the main strengths of the VINCI Group’s business model:
- key player to capture the world’s megatrends;
- strong and resilient free cash flow;
- solid balance sheet;
- consistent and value-accretive capital allocation strategy;
- longstanding M&A track record with high-quality returns over time;
- alignment of interests, from employees to other shareholders;
- outperforming stock over time;
- aiming for an all-round performance.
About VINCI
VINCI is a world leader in concessions, energy solutions and construction, employing 285,000 people in more than 120 countries. We design, finance, build and operate infrastructure and facilities that help improve daily life and mobility for all. Because we believe in all-round performance, above and beyond economic and financial results, we are committed to operating in an environmentally and socially responsible manner. And because our projects are in the public interest, we consider that reaching out to all our stakeholders and engaging in dialogue with them is essential in the conduct of our business activities. VINCI’s ambition is to create long-term value for its customers, shareholders, employees, partners and society in general. www.vinci.com
This press release is an official information document of the VINCI Group.
PRESS CONTACT
VINCI Press Department
Tel: +33 (0)1 57 98 62 88
media.relations@vinci.com
Attachment
- CP VINCI_Publication PitchBook_19 05 2025_VA
- Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds - June 25, 2025
- WISeSat Signs a Service Agreement with Astrocast to Allow Access to Astrocast’s Operational Satellite Constellation - June 25, 2025
- Novartis announces expiration of Regulus Therapeutics tender offer - June 25, 2025
